Quinolone Ototoxicity in Ear Infections: Safety and Considerations

Safety Profile of Quinolone Eardrops

The American Academy of Otolaryngology-Head and Neck Surgery recommends quinolone eardrops as the preferred topical treatment for ear infections with non-intact tympanic membranes due to their lack of ototoxicity compared to aminoglycoside-containing alternatives 1, 2, 3
Topical quinolone antibiotics, such as ofloxacin and ciprofloxacin, are FDA-approved for use in ear infections with non-intact tympanic membranes because they lack the ototoxicity associated with aminoglycoside-containing eardrops 1, 3
Quinolone eardrops are considered safe even in children, as they do not have significant systemic absorption 2, 4

Topical quinolone therapy demonstrates superior clinical cure rates (77-96%) compared to systemic antibiotics (30-67%) for treating ear infections with tympanostomy tubes 1, 3
The high concentration achieved with topical application (up to 1000 times higher than systemic levels) allows quinolones to overcome bacterial resistance that might be reported in laboratory testing 2, 3
Quinolone eardrops provide better coverage against common ear pathogens, especially Pseudomonas aeruginosa 3, 5

Caregivers should limit topical quinolone therapy to a single course of no more than 10 days to prevent potential complications 2, 3
Prolonged or frequent use of quinolone eardrops may potentially induce fungal external otitis (otomycosis) 2, 4

Ensure the ear canal is cleaned of debris before administering drops to improve drug delivery to the middle ear 2, 7
Techniques to improve drug penetration include blotting the canal opening or using an infant nasal aspirator to remove secretions, using tissue spears to clean the external auditory canal, and having the caregiver "pump" the tragus several times after instilling drops 1, 2, 7

For granulation tissue or granuloma at the tympanostomy tube site, topical quinolone drops with or without dexamethasone are the treatment of choice 2
Systemic antibiotic therapy should be considered in addition to topical therapy when cellulitis of the pinna or adjacent skin is present, concurrent bacterial infection exists elsewhere, signs of severe infection are present, or acute otorrhea persists despite topical therapy 4, 7